> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Genentech Gains Shorter Infusion Time with MS Drug
- URL: https://www.fdaweb.com/genentech-gains-shorter-infusion-time-with-ms-drug/
- Published: 2020-12-14T12:00:00.000Z
- Updated: 2026-09-14T16:40:04.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5148297

FDA has approved a shorter two-hour infusion time for Genentech’s Ocrevus (ocrelizumab) — dosed twice-yearly for those living with relapsing or primary progressive multiple sclerosis (MS) who have not experienced any prior serious infusion reactions (IRs). The dosing approval was based on data from the randomized, double-blind ENSEMBLE PLUS study. The NDA for Ocrevus was approved in 2017 as an intravenous infusion for treating adult patients with relapsing forms of MS and primary progressive multiple sclerosis ([see earlier story](https://www.fdaweb.com/login.php?sa=v&aid=D5138324&searchWords=Ocrevus&cate=S&stid=%241%24y10.T%2F0.%24l.ECFH6sWqVGyyjwjies71)).